Quest Diagnostics Inc.
DGXBusiness Overview
ticker: DGX step: 01 generated: 2026-05-13 source: quick-research
Quest Diagnostics Inc. (DGX) — Business Overview
Business Description
Quest Diagnostics is the largest independent clinical laboratory network in the United States, processing approximately 170 million patient encounters annually across 2,250+ patient service centers and 50+ laboratories. The company provides diagnostic testing, information, and services to patients, physicians, hospitals, and health plans — generating revenue from the volume of laboratory test requisitions processed. FY2025 revenue was $11.04B, up 11.8% YoY driven by acquisitions and strong organic volume growth.
Revenue Model
Quest earns per-test fees billed to commercial insurers (~55% of revenue), government payers Medicare/Medicaid (~25%), and patients/other (~20%). Revenue per requisition varies dramatically by test complexity — a routine blood panel earns $20-30 while an advanced genomic test can earn $800-2,000+. The business is high-volume/lower-margin at the commodity end (routine chemistry) but high-margin at the specialty/advanced end (genomics, oncology, neurology). Volume growth and mix shift toward advanced diagnostics are the key drivers of revenue and margin expansion.
Products & Services
- Routine Diagnostics: CBC, metabolic panels, lipid panels, HbA1c, urinalysis — bread-and-butter primary care tests
- Advanced Diagnostics: Molecular genomics, oncology biomarker testing, pharmacogenomics, brain health (AD-Detect Alzheimer's), advanced cardiometabolic panels
- Infectious Disease: STI panels, respiratory (flu/COVID/RSV), hepatitis, HIV
- Consumer Health: questhealth.com — direct-to-consumer testing platform (150+ tests)
- Hospital Outreach: Lab management and outreach services for health systems
Customer Base & Go-to-Market
Physicians order ~70% of tests (primary care + specialists); hospitals and health systems order ~20%; direct consumers ~10%. Quest has national health plan contracts covering 90%+ of in-network commercial lives nationwide. Key payer relationships: Elevance Health and Sentara Health Plans (expanded collaboration effective Jan 2025). The company has deployed an Epic integration (Project Nova) to streamline order-to-cash workflows with health systems.
Competitive Position
Quest is the #1 independent lab in the U.S. by revenue and volume, competing primarily with Labcorp (#2) and a fragmented tail of regional hospital labs. Scale provides lower cost-per-test economics, broader test menu, and national payer contract leverage. The company has been consolidating hospital outreach lab operations (8 acquisitions in 2024 alone, including LifeLabs in Canada) — a strategy that converts formerly captive hospital volumes to Quest's higher-margin independent lab platform.
Key Facts
- Founded: 1967 (as MetPath)
- Headquarters: Secaucus, NJ
- Employees: ~50,000
- Exchange: NYSE
- Sector / Industry: Health Care / Health Care Providers & Services
- Market Cap: ~$17B
Financial Snapshot
ticker: DGX step: 04 generated: 2026-05-13 source: quick-research
Quest Diagnostics Inc. (DGX) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | $9.88B | $9.25B | $9.87B | +6.7% |
| Gross Margin | ~33% | ~33% | ~33% | |
| Operating Margin | ~16% | ~14% | ~14% | |
| Net Income | ~$970M | ~$730M | ~$750M | +2.7% |
| EPS (adjusted diluted) | ~$10.00 | ~$8.71 | ~$8.93 | +2.5% |
FY2022 elevated by residual COVID testing revenue. FY2023 decline reflects COVID normalization (~$500M+ revenue loss). FY2024 recovered on organic base growth (+3-4% ex-acquisitions) + acquisition contributions. FY2025: $11.04B revenue (+11.8%), adjusted EPS $9.85 — strong Q4 beat driven by LifeLabs + hospital outreach acquisitions.
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| Operating Cash Flow | $1.33B |
| Free Cash Flow | ~$879M ($1.33B OCF − $454M capex) |
| Capital Expenditures | $454M |
| Cash & Equivalents | ~$600M |
| Total Debt | ~$5.0B |
| Adjusted EBITDA | ~$1.8B (~18% margin) |
Key Ratios (approximate)
- P/E: ~18x (adjusted) | EV/EBITDA: ~13x | FCF Yield: ~5%
- Revenue Growth (FY2025): +11.8% (acquisitions + organic) | Organic growth: ~4-5%
- Gross Margin: ~33% (consistent) | EBITDA Margin: ~18%
- Net Debt / EBITDA: ~2.5x — manageable for stable cash flow business
Growth Profile
Quest's "true" organic growth rate is mid-single digits — the COVID boom/bust created a distorted 2022-2023 comparison. Excluding COVID revenue, the core diagnostic testing business grows at ~4-5% annually through a combination of volume growth and mix shift toward higher-value advanced testing (oncology, genomics, brain health). Acquisition strategy is consistent: buying hospital outreach lab operations that bring captive volumes into Quest's lower-cost network. LifeLabs ($1.35B, closed 2024) added Canadian scale. FY2025 Q1 showed 11% volume growth YoY — among the highest organic volume quarters in years.
Forward Estimates
- FY2026 guidance: $11.70-$11.82B revenue (+6-7%); diluted EPS $9.45-$9.65
- FY2025 adjusted EPS: $9.85 (beat consensus $9.72)
- Analyst consensus FY2026 adj. EPS: ~$9.55
- Dividend: $0.86/quarter ($3.44 annualized); 6.7% increase in 2025, 7.5% increase for 2026
- Mean analyst price target: ~$197 (12 analysts covering; consensus Hold)
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $DGX.